Cargando…
Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III
BACKGROUND: The purpose of the study was to analyse whether the levels of the tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) are higher in patients with rectal cancer as compared with healthy blood donors. PATIENTS AND METHODS. Two hundred and seventeen patients (147 male, 70 female) with...
Autores principales: | Oblak, Irena, Anderluh, Franc, Velenik, Vaneja, Mozina, Barbara, Ocvirk, Janja, Ciric, Eva, Podvrsnik, Natasa Hrovatic |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Versita, Warsaw
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423738/ https://www.ncbi.nlm.nih.gov/pubmed/22933958 http://dx.doi.org/10.2478/v10019-011-0027-2 |
Ejemplares similares
-
The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer
por: Oblak, Irena, et al.
Publicado: (2013) -
Cetuximab in preoperative treatment of rectal cancer – term outcome of the XERT trial
por: Velenik, Vaneja, et al.
Publicado: (2012) -
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer
por: Velenik, Vaneja, et al.
Publicado: (2010) -
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
por: Velenik, Vaneja, et al.
Publicado: (2011) -
Long term outcome after combined modality treatment for anal cancer
por: Oblak, Irena, et al.
Publicado: (2012)